Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
WT4869 is a synthetic peptide vaccine derived from the Wilms’ tumor gene 1 (WT1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of WT4869, and biomarkers for response, in patients with myelodysplastic syndrome. WT4869 (5–1200 μg/dose) was administered intradermally every 2 weeks, according to a 3 + 3 dose‐escalation method in higher‐risk (International Prognostic Scoring System score ≥1.5) or lower‐risk (score
CONCLUSION: The results demonstrate ethnic, race, age and gender disparities in iCCA incidence and survival, and confirm continued increase in iCCA incidence in the United States. PMID: 29469047 [PubMed - in process]
The infection rate has begun to decline, but there are likely to be many deaths before the flu season finally ends.
Enzalutamide may have a role in prostate cancer therapy, but randomized trials are needed, says Dr Chodak.Medscape Urology
February 23, 2018—(BRONX, NY)—Earlier this week, in a crowded conference room in the Price Center/Block Pavilion, members of the Einstein-Montefiore community hosted a special visit from U.S. Congressman Joseph Crowley (D-NY, 14th District). At his office’s request, Rep. Crowley met with more than a dozen BOLD Buddies, volunteer peer mentors who provide support for cancer patients and survivors in the Bronx. Members of the group shared their personal stories and explained commitment to offer their support, hope and encouragement to others facing cancer and treatment at all stages of disease.
Conclusions: Owing to increasing incidence and declining mortality, the number of sepsis survivors at risk for hospital readmission rose significantly between 2010 and 2015. The 30-day hospital readmission rates for sepsis declined modestly but were offset by a rise in emergency department treat-and-release visits.
Conclusions: Our data suggest that targeting the sphingosine kinase 1–/sphingosine-1-phosphate–/sphingosine-1-phosphate receptor 2–signaling pathway in the lung may provide a novel therapeutic perspective in pneumococcal pneumonia for prevention of acute lung injury.
No abstract available
Abstract WT4869 is a synthetic peptide vaccine derived from the Wilms’ tumor gene 1 (WT1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of WT4869, and biomarkers for response, in patients with myelodysplastic syndrome. WT4869 (5–1200 μg/dose) was administered intradermally every 2 weeks, according to a 3+3 dose‐escalation method in higher‐risk (International Prognostic Scoring System score ≥1.5) or lower‐risk (score
Background: Myelodysplastic Syndrome (MDS) is a disorder of the bone marrow wherein hematopoietic cells fail to develop and differentiate into their mature forms. High iron stores in the body are known to have a detrimental effect on the overall outcome for the patient, however its exact role in the disease spectrum is currently unknown. We sought out to elucidate the role of Serum Ferritin against two end points - infection and death.Methods: The patient data was queried from METEOR (Methodist Environment for Translational Enhancement and Outcomes Research), a clinical data warehouse and analytics environment. We obtained...